In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ensuring Big Pharma Doesn’t Turn Specialty Markets Into Primary Care

Executive Summary

Lured by the success of Abbott in rheumatology, Novartis in oncology, and Genzyme in orphan/genetic diseases, pharmaceutical manufacturers have turned their collective sights on specialist-driven markets. But payor pressure is ballooning and as examples in these hotly competitive areas demonstrate, to truly succeed in specialist markets, companies cannot rely on a ‘follower’ strategy. Instead, careful selection of indications where true innovation is possible and fostering meaningful interaction with physicians and patient communities will allow pharmaceutical companies to grow specialty franchises alongside traditional strengths.

Advertisement

Related Content

New Ecosystems In Pharma: Maturing Markets Mean New Models Are Needed
The Sanofi Relationship Supports Regeneron’s FIBCO Strategy
Multiple Sclerosis Drug Category Heats Up; So Does Spending
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Oral Molecules In An Injectable World: What Developers Need To Do Now
Launching Ampyra: What Drug Companies Can Learn From The Experience
Reimbursement: The New Biopharma Investment Hurdle
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel